Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Good news regarding Necuparanib for patients & MNTA investors -

Necuparanib Inhibits Pancreatic Cancer Progression and Invasion in a 3D Tumor and Stromal Cell Co-Culture System, AACR 2016

Presented at the AACR Special Conference on The
Function of Tumor Microenvironment in Cancer Progression

January 7 –10, 2016
San Diego, California, USA

The ability to inhibit proliferation in both tumor and stromal cells and enhance the therapeutic effect of gemcitabine demonstrates that necuparanib is a promising multitargeting agent for difficult-to-treat cancers such as desmoplastic pancreatic tumors. These findings support the current Phase 1/2 safety and efficacy study being performed in patients with metastatic pancreatic cancer.

http://www.momentapharma.com/docs/AACR-2016-January-poster-6x4-WEB.pdf